[go: up one dir, main page]

AR049374A1 - Sintesis de compuestos de ester y acido borico - Google Patents

Sintesis de compuestos de ester y acido borico

Info

Publication number
AR049374A1
AR049374A1 ARP050101205A ARP050101205A AR049374A1 AR 049374 A1 AR049374 A1 AR 049374A1 AR P050101205 A ARP050101205 A AR P050101205A AR P050101205 A ARP050101205 A AR P050101205A AR 049374 A1 AR049374 A1 AR 049374A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
aromatic
formula
boric acid
ester
Prior art date
Application number
ARP050101205A
Other languages
English (en)
Inventor
Fraser Pickersgill
John Bishop
Christoph Koellner
Jean-Marc Gomez
Achim Geiser
Robert Hett
Vince Ammoscato
Stephen Munk
Young Lo
Fang-Ting Chiu
Vithalanand R Kulkarni
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34968044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049374(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of AR049374A1 publication Critical patent/AR049374A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)

Abstract

La presente se refiere a la síntesis de compuestos de éster y ácido borico. Proporciona procesos sintéeticos mejorados para la produccion a gran escala de compuestos de éster y ácido borico, incluyendo el inhibidor de proteasoma péptico de ácido borico bortezomib. Reivindicacion 1: Un proceso a gran escala para preparar un compuesto de +ester borico de formula (1) en la que: R1 es un grupo alifático, aromático o heteroaromático opcionalmente sustituido; R2 es H, un grupo nucleofugo o un grupo alifático, aromático o heteroaromático opcionalmente sustituido; R3 es un grupo nucleofugo o un grupo alifático, aromático o heteroaromático opcionalmente sustituido; y cada uno de R4 y R5, independientemente, es un grupo alifático, aromático o heteroaromático opcionalmente sustituido o R4 y R5, tomados junto con los átomos de O y boro que intervienen, forman un anillo de 5 a 10 miembros opcionalmente sustituidos que tiene 0-2 heteroátomos más en el anillo seleccionados entre N, O o S; comprendiendo dicho procso las etapas: (a) proporcionar un complejo boron"ato" de formula (2) en la que Y es un grupo nucleofugo; M+ es un cation; y cada uno de R1 a R5 es como se ha definido anteriormente; y (b) poner en contacto el complejo boron"ato" de formula (2) con un ácido de Lewis en condiciones que produzcan el compuesto de éster borico de formula (1), realizándose dicha etapa de contacto en una mezcla de reaccion que comprende: (i) un disolvente de éter de coordinacion que tiene una baja miscibilidad con agua; o (ii) un disolvente e éter que tiene una baja miscibilidad con agua y un co-disolvente de coordinacion.
ARP050101205A 2004-03-30 2005-03-30 Sintesis de compuestos de ester y acido borico AR049374A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55753504P 2004-03-30 2004-03-30

Publications (1)

Publication Number Publication Date
AR049374A1 true AR049374A1 (es) 2006-07-26

Family

ID=34968044

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP050101205A AR049374A1 (es) 2004-03-30 2005-03-30 Sintesis de compuestos de ester y acido borico
ARP140103013A AR097310A2 (es) 2004-03-30 2014-08-11 Síntesis de compuestos de éster y ácido bórico
ARP140103012A AR097309A2 (es) 2004-03-30 2014-08-11 Un proceso a gran escala para preparar un compuesto de éster aminobórico

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP140103013A AR097310A2 (es) 2004-03-30 2014-08-11 Síntesis de compuestos de éster y ácido bórico
ARP140103012A AR097309A2 (es) 2004-03-30 2014-08-11 Un proceso a gran escala para preparar un compuesto de éster aminobórico

Country Status (41)

Country Link
US (14) US7714159B2 (es)
EP (5) EP2377868A1 (es)
JP (4) JP4558039B2 (es)
KR (1) KR100939598B1 (es)
CN (5) CN111925385B (es)
AR (3) AR049374A1 (es)
AT (1) ATE521612T1 (es)
AU (1) AU2005230930B2 (es)
BR (1) BRPI0509587A (es)
CA (4) CA2738706C (es)
CL (2) CL2010000350A1 (es)
CR (1) CR8653A (es)
CY (3) CY1112053T1 (es)
DK (4) DK3385267T3 (es)
DO (1) DOP2011000293A (es)
EA (1) EA012927B1 (es)
EC (1) ECSP066960A (es)
ES (4) ES2371652T3 (es)
FI (1) FI4008721T3 (es)
HK (1) HK1246300A1 (es)
HR (4) HRP20212002T1 (es)
HU (2) HUE065769T2 (es)
IL (3) IL178250A (es)
LT (2) LT4008721T (es)
ME (1) ME01975B (es)
MX (1) MX367324B (es)
MY (1) MY145427A (es)
NL (3) NL1028639C2 (es)
NO (4) NO338905B1 (es)
NZ (3) NZ598172A (es)
PE (3) PE20060162A1 (es)
PL (4) PL3385267T3 (es)
PT (4) PT1756121E (es)
RS (4) RS65253B1 (es)
SG (5) SG10201600029PA (es)
SI (4) SI2377869T1 (es)
TW (1) TWI386212B (es)
UA (1) UA90108C2 (es)
UY (3) UY28830A1 (es)
WO (1) WO2005097809A2 (es)
ZA (1) ZA200608689B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
RS65253B1 (sr) * 2004-03-30 2024-03-29 Millennium Pharm Inc Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline
WO2008075376A1 (en) * 2006-12-18 2008-06-26 Natco Pharma Limited Polymorphic forms of bortezomib and process for their preparation
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
KR20140042933A (ko) 2007-08-06 2014-04-07 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
US20100226597A1 (en) * 2007-09-12 2010-09-09 Dr. Reddy's Laboratories Limited Bortezomib and process for producing same
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EA030685B1 (ru) 2008-06-17 2018-09-28 Милленниум Фармасьютикалз, Инк. Способ получения соединения боронатного эфира
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AU2013204874B2 (en) * 2008-09-29 2016-11-10 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
CN101899062B (zh) * 2009-05-26 2015-04-15 上海威智医药科技有限公司 α-手性硼酸及硼酸酯的合成工艺
EP2270019A1 (en) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
EP2280016A1 (en) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
JP2012530116A (ja) 2009-06-19 2012-11-29 レツク・フアーマシユーテイカルズ・デー・デー 脱ハロゲン化なしにハロゲノアルケンを水素化する方法
EP2516449A1 (en) 2009-12-22 2012-10-31 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
WO2011090940A1 (en) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
EP2534159A1 (en) 2010-02-09 2012-12-19 Ranbaxy Laboratories Limited Process for the preparation of bortezomib
CN101781326B (zh) * 2010-02-11 2013-08-21 福建南方制药股份有限公司 一种制备手性氨基硼酸的中间体及其制备方法
WO2011107912A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Polymorphic forms of bortezomib
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
WO2011116286A2 (en) * 2010-03-18 2011-09-22 Innopharma, Llc Stable bortezomib formulations
US8513218B2 (en) 2010-03-31 2013-08-20 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
EP2571525A4 (en) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions and methods for treating autoimmune and other diseases
EP2627636B1 (en) 2010-10-14 2015-09-02 Synthon BV Process for making bortezomib and the intermediates for the process
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
CN102206188B (zh) * 2011-04-08 2013-02-27 苏州二叶制药有限公司 N-(吡嗪-2-基羰基)-l-苯丙氨酸的制备方法
US8497374B2 (en) 2011-05-12 2013-07-30 Scinopharm Taiwan, Ltd. Process for preparing and purifying bortezomib
CN102268029B (zh) * 2011-05-19 2013-10-09 苏州二叶制药有限公司 化合物（1s,2s,3r,5s）-蒎烷二醇-l-苯丙氨酸-l-亮氨酸硼酸酯的制备
MX2013015308A (es) 2011-06-22 2014-05-20 Cephalon Inc Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
CN102351890B (zh) * 2011-09-30 2014-07-02 重庆泰濠制药有限公司 一种硼替佐米的合成方法
CN102492021B (zh) * 2011-12-13 2013-10-23 重庆泰濠制药有限公司 硼替佐米的制备工艺
JP6129203B2 (ja) * 2011-12-22 2017-05-17 アレス トレーディング ソシエテ アノニム α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤
CN103374026A (zh) * 2012-04-27 2013-10-30 重庆医药工业研究院有限责任公司 一种硼替佐米中间体的制备方法
CN103450331B (zh) * 2012-06-05 2016-05-25 山东新时代药业有限公司 一种硼替佐米的精制方法
JP2015532915A (ja) * 2012-09-11 2015-11-16 シプラ・リミテッド ボルテゾミブの製造方法
WO2014072985A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
EP2919786A4 (en) 2012-11-16 2016-06-01 Shilpa Medicare Ltd Crystalline bortezomib process
JP6403219B2 (ja) 2012-12-07 2018-10-10 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
CN103897027A (zh) * 2012-12-29 2014-07-02 曹亚英 关键中间体晶型，制备方法及其在硼替佐米合成中的运用
CN103897026A (zh) * 2012-12-29 2014-07-02 朱继东 硼替佐米关键中间体的晶型，制备方法及其运用
ES2730013T3 (es) 2013-01-10 2019-11-07 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
ZA201402789B (en) 2013-04-16 2015-11-25 Cipla Ltd Process for the preparation of bortezomib mannitol ester
CN104211758B (zh) * 2013-05-29 2020-06-12 深圳翰宇药业股份有限公司 一种硼替佐米的制备方法
CN103497233B (zh) * 2013-09-30 2015-04-08 哈药集团技术中心 一种硼替佐米的制备方法
CN103554219A (zh) * 2013-10-01 2014-02-05 昆明贵研药业有限公司 一种制备硼替佐米的方法
KR101691353B1 (ko) * 2013-12-09 2016-12-30 주식회사 경보제약 보르테조밉의 제조방법 및 그의 신규 중간체
EP3102585B1 (en) 2014-02-03 2021-05-19 Ohio State Innovation Foundation Boronic acid esters and pharmaceutical formulations thereof
UY36132A (es) 2014-05-20 2015-11-30 Millennium Pharm Inc Métodos para terapia de cáncer
HRP20210693T1 (hr) 2014-06-11 2021-06-11 VenatoRx Pharmaceuticals, Inc. Inhibitori beta-laktamaze
JP6420629B2 (ja) * 2014-10-30 2018-11-07 ボーグワーナー インコーポレーテッド チェーンガイドおよびチェーンテンショナアーム
DE102015204151B4 (de) * 2015-03-09 2025-12-24 Adidas Ag Ball, insbesondere Fußball, und Verfahren zur Herstellung eines Balls
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
WO2018150386A1 (en) 2017-02-17 2018-08-23 Fresenius Kabi Oncology Ltd. An improved process for the preparation of boronic acid esters
IL301591B1 (en) 2017-03-06 2025-11-01 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
CN109305980B (zh) 2017-07-28 2022-10-11 成都奥璟生物科技有限公司 一种硼酸酯化合物、其合成方法及其用途
EP3676272A4 (en) 2017-09-02 2021-04-21 Sun Pharmaceutical Industries Limited IXAZOMIB CITRATE PREPARATION PROCESS
EP3802551A4 (en) 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN111187336B (zh) * 2018-11-14 2022-05-20 正大天晴药业集团股份有限公司 硼替佐米的精制方法
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process
WO2025034812A2 (en) 2023-08-07 2025-02-13 Tae Life Sciences Llc Trifluoroborate (bf3) compositions for use in boron neutron capture therapy and methods thereof
WO2025080942A1 (en) * 2023-10-13 2025-04-17 The Brigham And Women’S Hospital, Inc. Proteasome inhibitors and methods of use thereof
CN120248757A (zh) * 2025-05-28 2025-07-04 滁州瑞达新能源材料有限公司 一种自清洁耐候的铝合金光伏组件边框及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31992A (en) * 1968-05-08 1973-07-30 American Cyanamid Co Synthetic thyrocalcitonins and method of making them
ZA794723B (en) * 1978-09-11 1980-08-27 Univ Miami Anti-hypertensive agents
US4525309A (en) * 1983-03-15 1985-06-25 Washington State University Research Foundation, Inc. Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
ES8603405A1 (es) * 1985-04-22 1985-12-16 Inke Sa "procedimiento para la obtencion del ester benzilico de 1-(n-(1--etoxicarbonil-3-oxo-fenilpropil)-l-alanil)-l-prolina".
SE8506094D0 (sv) * 1985-12-20 1985-12-20 Astra Laekemedel Ab New antibacterial agents and intermediates therefor
US4701545A (en) * 1986-02-12 1987-10-20 Washington State University Research Foundation, Inc. Preparation of α,α-dihaloalkyl boronic esters
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2435124A1 (en) * 2001-01-25 2002-08-01 Millennium Pharmaceuticals, Inc. Formulation of boronic acid compounds
JPWO2003033507A1 (ja) 2001-10-12 2005-02-03 杏林製薬株式会社 ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬
JPWO2003033506A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
RS65253B1 (sr) * 2004-03-30 2024-03-29 Millennium Pharm Inc Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
JP2012530116A (ja) * 2009-06-19 2012-11-29 レツク・フアーマシユーテイカルズ・デー・デー 脱ハロゲン化なしにハロゲノアルケンを水素化する方法

Also Published As

Publication number Publication date
DK4008721T3 (da) 2024-03-25
NO20171939A1 (no) 2006-12-22
HK1100004A1 (en) 2007-08-31
EP1756121B1 (en) 2011-08-24
RS62738B1 (sr) 2022-01-31
MX367324B (es) 2019-08-15
TW200616646A (en) 2006-06-01
US7714159B2 (en) 2010-05-11
US20050240047A1 (en) 2005-10-27
CN103396427B (zh) 2018-04-13
SI2377869T1 (sl) 2014-05-30
CN107474062A (zh) 2017-12-15
WO2005097809A2 (en) 2005-10-20
CA2560886A1 (en) 2005-10-20
AU2005230930B2 (en) 2011-09-29
NO343966B1 (no) 2019-07-29
ES2457593T3 (es) 2014-04-28
CA2738706A1 (en) 2005-10-20
US20210171574A1 (en) 2021-06-10
ZA200608689B (en) 2007-09-26
DK1756121T3 (da) 2012-01-09
SI1756121T1 (sl) 2012-03-30
IL219856A0 (en) 2012-06-28
HK1246300A1 (zh) 2018-09-07
JP2007530687A (ja) 2007-11-01
US20150038706A1 (en) 2015-02-05
EP4008721B1 (en) 2024-01-03
ES2371652T3 (es) 2012-01-05
KR100939598B1 (ko) 2010-02-01
HK1257298A1 (zh) 2019-10-18
UY35578A (es) 2016-01-08
IL219853A (en) 2015-05-31
ES2899606T3 (es) 2022-03-14
NL1033189C2 (nl) 2008-08-14
CA2738706C (en) 2014-10-14
DOP2011000293A (es) 2011-12-15
JP5414625B2 (ja) 2014-02-12
SI4008721T1 (sl) 2024-05-31
NO20064893L (no) 2006-12-22
NL1033190A1 (nl) 2007-04-23
JP6193960B2 (ja) 2017-09-06
NO338905B1 (no) 2016-10-31
FI4008721T3 (fi) 2024-03-19
IL178250A0 (en) 2006-12-31
EP2377869A1 (en) 2011-10-19
PL1756121T3 (pl) 2012-02-29
CL2014002252A1 (es) 2014-12-05
CN111925385A (zh) 2020-11-13
NO20191065A1 (no) 2006-12-22
JP2013100378A (ja) 2013-05-23
RS65253B1 (sr) 2024-03-29
AR097309A2 (es) 2016-03-02
HRP20212002T1 (hr) 2022-04-01
SG182998A1 (en) 2012-08-30
NL1028639C2 (nl) 2007-01-17
RS51983B (sr) 2012-02-29
US20130005968A1 (en) 2013-01-03
HUE065769T2 (hu) 2024-06-28
US20190330270A1 (en) 2019-10-31
US20200157143A1 (en) 2020-05-21
PE20142402A1 (es) 2015-02-04
NZ598172A (en) 2013-08-30
AR097310A2 (es) 2016-03-02
SG151322A1 (en) 2009-04-30
CL2010000350A1 (es) 2011-01-28
UY28830A1 (es) 2005-09-30
NL1033189A1 (nl) 2007-10-22
EP4008721A1 (en) 2022-06-08
US20220204558A1 (en) 2022-06-30
ME01975B (me) 2015-05-20
PL4008721T3 (pl) 2024-05-13
PT1756121E (pt) 2011-11-30
RS53259B (sr) 2014-08-29
CY1115336T1 (el) 2017-01-04
CN108329337B (zh) 2021-06-25
PE20110075A1 (es) 2011-02-17
EA012927B1 (ru) 2010-02-26
US10000529B2 (en) 2018-06-19
SI3385267T1 (sl) 2022-04-29
ECSP066960A (es) 2006-12-20
SG182999A1 (en) 2012-08-30
US20180044377A1 (en) 2018-02-15
KR20070007873A (ko) 2007-01-16
JP2010241816A (ja) 2010-10-28
PE20060162A1 (es) 2006-04-07
CN1960996A (zh) 2007-05-09
HRP20240307T3 (hr) 2024-05-10
NL1028639A1 (nl) 2005-10-20
CA2859119A1 (en) 2005-10-20
EP2377868A1 (en) 2011-10-19
EA200601795A1 (ru) 2007-04-27
JP4558039B2 (ja) 2010-10-06
TWI386212B (zh) 2013-02-21
AU2005230930A1 (en) 2005-10-20
EP2377869B1 (en) 2014-01-29
NZ586824A (en) 2012-03-30
US20210395301A1 (en) 2021-12-23
EP3385267A1 (en) 2018-10-10
CN111925385B (zh) 2023-11-21
PL3385267T3 (pl) 2022-02-14
JP2016056180A (ja) 2016-04-21
PT2377869E (pt) 2014-04-15
SG10201800972PA (en) 2018-03-28
US20190112334A1 (en) 2019-04-18
CR8653A (es) 2007-10-23
IL178250A (en) 2012-06-28
PT4008721T (pt) 2024-03-21
NO344610B1 (no) 2020-02-10
CY1112053T1 (el) 2015-11-04
IL219856A (en) 2015-05-31
HRP20110846T1 (hr) 2011-12-31
EP3385267B1 (en) 2021-09-29
NZ550522A (en) 2010-08-27
HRP20140339T1 (hr) 2014-05-09
UA90108C2 (uk) 2010-04-12
HK1164320A1 (en) 2012-10-19
IL219853A0 (en) 2012-06-28
SG10201600029PA (en) 2016-02-26
US9862745B2 (en) 2018-01-09
BRPI0509587A (pt) 2007-09-25
UY34969A (es) 2015-02-27
US8283467B2 (en) 2012-10-09
US20180265546A1 (en) 2018-09-20
WO2005097809A3 (en) 2006-02-16
NO20161350A1 (no) 2006-12-22
MY145427A (en) 2012-02-15
CA2853272A1 (en) 2005-10-20
CN103396427A (zh) 2013-11-20
CY1124753T1 (el) 2022-07-22
EP1756121A2 (en) 2007-02-28
CN108329337A (zh) 2018-07-27
LT4008721T (lt) 2024-03-25
DK2377869T3 (da) 2014-04-14
ATE521612T1 (de) 2011-09-15
CN1960996B (zh) 2016-04-20
HUE056859T2 (hu) 2022-03-28
PT3385267T (pt) 2021-11-23
DK3385267T3 (da) 2021-11-01
CA2560886C (en) 2014-08-12
PL2377869T3 (pl) 2014-07-31
US20200369722A1 (en) 2020-11-26
LT3385267T (lt) 2021-11-10
JP5894952B2 (ja) 2016-03-30
ES2974758T3 (es) 2024-07-01
NL1033190C2 (nl) 2007-11-27
US20100174072A1 (en) 2010-07-08
US20160362449A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
AR049374A1 (es) Sintesis de compuestos de ester y acido borico
CO6140053A2 (es) Proceso para fabricar 2-amino-5-halobenzamidas 3-sustituidas
BR112012008939A2 (pt) processo para a preparação de compostos úteis como inibidores de sglt2
PE20150282A1 (es) Nuevos compuestos bifuncionales utiles como ligando de uranios (vi), metodos de sintesis de los mismos y usos de los mismos
EA201201179A1 (ru) Способ получения изоксазолиновых производных
CO6640266A2 (es) Proceso para preparar derivados de dihidropirrol
AR043443A1 (es) Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios
AR123584A2 (es) Procesos y compuestos intermediarios para la preparación de derivados de 2-carboxamida-cicloamino-urea
AR109669A1 (es) Proceso para preparar 2-exo-(2-metilbenciloxi)-1-metil-4-isopropil-7-oxabiciclo[2.2.1]heptano
AR084864A1 (es) Proceso de preparacion de girasa e inhibidores de topoisomerasa iv y compuestos intermediarios de dicho proceso
MX2015010934A (es) Metodo para producir un compuesto triciclico, y un compuesto triciclico capaz de producirse por dicho metodo de produccion.
CN103214446B (zh) 一种色满酮衍生物的不对称合成方法
AR075441A1 (es) Un proceso para la preparacion de etoricoxib
AR081399A1 (es) Proceso para preparar un compuesto de pirimidinona, compuestos intermediarios en dicho proceso y procesos para repararlos.
MA35906B1 (fr) Procédé de préparation d'un composé par le biais d'une nouvelle réaction d'addition de michael en utilisant de l'eau ou divers acides comme additifs
AR049668A1 (es) Proceso quimico para preparar esteres de 4,4 - difluorometil - 3 - oxo - butanoico por reaccion entre una amida y un ester.
ES2523717T3 (es) Método para preparar epoxi-cetonas quirales
MX2009004979A (es) Sales de acidos dihidroxiantraquinona carboxilicos y su uso terapeutico.
AR058171A1 (es) Procesos para la preparacion de derivados de ciclopropilamida
AR077823A1 (es) Proceso para preparar compuestos de benzimidazol sustituidos con 2-arilamino o heteroarilamino
AR051936A1 (es) Proceso para la preparacion de pirazoles
AR069311A1 (es) Proceso para preparar (r)-5-(2-aminoetil)-1-(6,8-difluorocroman-3-il)-1,3-dihidroimidazol-2-tiona y compuestos intermediarios de sintesis
CO5580784A2 (es) Proceso para la reaccion de alcaloides y uso de los productos de reaccion en la preparacion de medicamentos
AR046873A1 (es) Proceso para la preparacion de aminoalcoholes sustituidos
AR092071A1 (es) Proceso para la preparacion de derivados de ester heterociclicos

Legal Events

Date Code Title Description
FG Grant, registration